<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pirogovestnik</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник Национального медико-хирургического центра им. Н.И. Пирогова</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Pirogov National Medical &amp; Surgical Center</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-8255</issn><issn pub-type="epub">2782-3628</issn><publisher><publisher-name>Национальный медико-хирургический Центр им. Н.И. Пирогова</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25881/20728255_2026_21_1_146</article-id><article-id custom-type="elpub" pub-id-type="custom">pirogovestnik-549</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>ПРОГНОЗИРОВАНИЕ ОСЛОЖНЕНИЙ ПРИ ТЕРАПИИ COVID-19: ИСПОЛЬЗОВАНИЕ БИОМАРКЕРОВ И КЛИНИЧЕСКИХ ПОКАЗАТЕЛЕЙ</article-title><trans-title-group xml:lang="en"><trans-title>PREDICTION OF COMPLICATIONS IN COVID-19 THERAPY: USE OF BIOMARKERS AND CLINICAL INDICATORS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колотилина</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolotilina</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Yekaterinburg</p></bio><email xlink:type="simple">mar_kol@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мартишина</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Martishina</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Волгоград</p></bio><bio xml:lang="en"><p>Volgograd</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Cухоруков</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukhorukov</surname><given-names>R. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Волгоград</p></bio><bio xml:lang="en"><p>Volgograd</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тузов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tuzov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Винникова</surname><given-names>М. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinnikova</surname><given-names>M. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Екатеринбург</p></bio><bio xml:lang="en"><p>Yekaterinburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural state medical university</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО Волгоградский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd state medical university</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО Санкт-Петербургский государственный педиатрический медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg state pediatric medical university</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>21</day><month>03</month><year>2026</year></pub-date><volume>21</volume><issue>1</issue><fpage>146</fpage><lpage>150</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Колотилина М.А., Мартишина Е.Е., Cухоруков Р.В., Тузов В.В., Винникова М.Д., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Колотилина М.А., Мартишина Е.Е., Cухоруков Р.В., Тузов В.В., Винникова М.Д.</copyright-holder><copyright-holder xml:lang="en">Kolotilina M.A., Martishina E.E., Sukhorukov R.V., Tuzov V.V., Vinnikova M.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://submit.pirogov-vestnik.ru/jour/article/view/549">https://submit.pirogov-vestnik.ru/jour/article/view/549</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование: В условиях глобальной пандемии, вызванной SARS-CoV-2, важнейшим фактором в обеспечении благоприятных исходов лечения стало своевременное и точное выявление пациентов с высоким риском осложнений. Одной из перспективных методик, способствующих такому выявлению, является использование биомаркеров, которые позволяют прогнозировать осложнения и тяжесть течения COVID-19.</p></sec><sec><title>Цель</title><p>Цель: оценка прогностической значимости различных биомаркеров у пациентов с COVID-19 и определение значимости разработки стандартизированных протоколов для мониторинга этих показателей в условиях пандемии. Материалы и методы: Для анализа были рассмотрены данные исследований, посвященных роли биомаркеров, таких как С-реактивный белок, D-димер, ферритин, лактатдегидрогеназа и тропонины, в прогнозировании осложнений у пациентов с COVID-19. Источники включали публикации в международных рецензируемых журналах, результаты клинических испытаний и мета-анализы, доступные в научных базах данных.</p></sec><sec><title>Результаты</title><p>Результаты: Повышенные уровни биомаркеров, таких как С-реактивный белок, D-димер, ферритин, лактатдегидрогеназа и тропонины, коррелируют с высоким риском острых осложнений, что делает их значимыми инструментами для мониторинга состояния пациентов. Внедрение унифицированных порогов для оценки тяжести состояния позволит снизить вариабельность данных и улучшить сопоставимость результатов между медицинскими учреждениями.</p></sec><sec><title>Заключение</title><p>Заключение: Данные подчеркивают значимость биомаркеров для мониторинга пациентов с COVID-19 и необходимость разработки стандартизированных протоколов для улучшения точности прогнозирования. Перспективы использования биомаркеров в адаптивных методах интенсивной терапии и реанимации являются важными направлениями для оптимизации исходов лечения и дальнейших исследований.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Rationale</title><p>Rationale: With the pandemic caused by SARS-CoV-2, accurate identification of patients at high risk for complications has become a key factor in ensuring positive treatment outcomes. A promising technique to facilitate such identification is the use of biomarkers that can predict complications and severity of COVID-19 course.</p></sec><sec><title>Objective</title><p>Objective: The purpose is to evaluate the prognostic significance of various biomarkers in individuals with COVID-19 and to determine the value of developing standardized protocols for monitoring these indicators under pandemic conditions.</p></sec><sec><title>Methods</title><p>Methods: For the analysis, we reviewed studies on the role of biomarkers such as C-reactive protein, D-dimer, ferritin, lactate dehydrogenase and troponins in predicting complications in patients with COVID-19. Sources used were international peer-reviewed journal publications, clinical trial results, and meta-analyses available in scientific databases.</p></sec><sec><title>Results</title><p>Results: Elevated levels of biomarkers such as C-reactive protein, D-dimer, ferritin, lactate dehydrogenase and troponins correlate with a high risk of acute complications, making them useful tools for monitoring. The common thresholds for assessing severity of illness will reduce data variability and improve comparability of results between healthcare providers.</p></sec><sec><title>Conclusion</title><p>Conclusion: The data highlights the importance of biomarkers for monitoring patients with COVID-19 and the need to develop standardized protocols to improve prognostic accuracy. Prospects for the use of biomarkers in adaptive critical care and resuscitation are important means to optimize patient outcomes and further research.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>биомаркеры</kwd><kwd>клинические показатели</kwd><kwd>прогнозирование осложнений</kwd><kwd>SARS-CoV-2</kwd><kwd>стандартизация диагностики</kwd><kwd>смертность</kwd><kwd>интенсивная терапия</kwd><kwd>С-реактивный белок</kwd><kwd>D-димер</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>biomarkers</kwd><kwd>clinical indicators</kwd><kwd>complication prediction</kwd><kwd>SARS-CoV-2</kwd><kwd>diagnostic standardization</kwd><kwd>mortality</kwd><kwd>intensive therapy</kwd><kwd>C-reactive protein</kwd><kwd>D-dimer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вспышка коронавирусной инфекции COVID-19. Всемирная организация здравоохранения. URL: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019.</mixed-citation><mixed-citation xml:lang="en">Вспышка коронавирусной инфекции COVID-19. Всемирная организация здравоохранения. URL: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Максимова Е.В., Морозов В.В. COVID-19 и глобализация // Инновации и инвестиции. – 2020. – №5. – С.86-90.</mixed-citation><mixed-citation xml:lang="en">Maksimova EV, Morozov VV. COVID-19 and globalization. Innovations and investments. 2020; 5: 86-90. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Абатуров А.Е., Агафонова Е.А., Кривуша Е.Л., Никулина А.А. Патогенез covid-19 // Здоровье ребёнка. – 2020. – Т.15. – №2. – С.133-144.</mixed-citation><mixed-citation xml:lang="en">Abaturov AE, Agafonova EA, Krivusha EA, Nikulina AA. The pathogenesis of Covid-19. Children’s Health. 2020; 15(2): 133-144. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Хайтович А.Б., Ермачкова П.А. Патогенез COVID-19 // Таврический медико-биологический вестник. – 2020. – Т.23. – №4. – С.113-132.</mixed-citation><mixed-citation xml:lang="en">Khaitovich AB, Yermachkova PA. The pathogenesis of COVID-19. Tavrichesky medico-biological bulletin. 2020; 23(4): 113-132. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ali AM, Rostam HM, Fatah MH, et al. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immunity, inflammation and disease. 2022; 10(3): e582. doi: 10.1002/iid3.582.</mixed-citation><mixed-citation xml:lang="en">Ali AM, Rostam HM, Fatah MH, et al. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immunity, inflammation and disease. 2022; 10(3): e582. doi: 10.1002/iid3.582.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in immunopathology. 2017; 39(5): 529-539. doi: 10.1007/s00281-017-0629-x.</mixed-citation><mixed-citation xml:lang="en">Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in immunopathology. 2017; 39(5): 529-539. doi: 10.1007/s00281-017-0629-x.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Xu R, Liu C, Xu X, et al. Role of cytokine storm in coronavirus infections: culprit or accomplice? Frontiers in Bioscience-Landmark. 2022; 27(3): 102. doi: 10.31083/j.fbl2703102.</mixed-citation><mixed-citation xml:lang="en">Xu R, Liu C, Xu X, et al. Role of cytokine storm in coronavirus infections: culprit or accomplice? Frontiers in Bioscience-Landmark. 2022; 27(3): 102. doi: 10.31083/j.fbl2703102.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Z, Wei Y, Tao C. An enlightening role for cytokine storm in coronavirus infection. Clinical Immunology. 2021; 222: 108615. doi: 10.1016/j.clim.2020.108615.</mixed-citation><mixed-citation xml:lang="en">Zhao Z, Wei Y, Tao C. An enlightening role for cytokine storm in coronavirus infection. Clinical Immunology. 2021; 222: 108615. doi: 10.1016/j.clim.2020.108615.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Reviews in medical virology. 2020; 30(6): 1-9. doi: 10.1002/rmv.2141.</mixed-citation><mixed-citation xml:lang="en">Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Reviews in medical virology. 2020; 30(6): 1-9. doi: 10.1002/rmv.2141.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Z, Long F, Yang Y, et al. Serum ferritin as an independent risk factor for severity in COVID-19 patients. Journal of infection. 2020; 81(4): 647-679. doi: 10.1016/j.jinf.2020.06.053.</mixed-citation><mixed-citation xml:lang="en">Lin Z, Long F, Yang Y, et al. Serum ferritin as an independent risk factor for severity in COVID-19 patients. Journal of infection. 2020; 81(4): 647-679. doi: 10.1016/j.jinf.2020.06.053.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou C, Chen Y, Ji Y, et al. Increased serum levels of hepcidin and ferritin are associated with severity of COVID-19. Medical science monitor: international medical journal of experimental and clinical research. 2020; 26: e926178. doi: 10.12659/MSM.926178.</mixed-citation><mixed-citation xml:lang="en">Zhou C, Chen Y, Ji Y, et al. Increased serum levels of hepcidin and ferritin are associated with severity of COVID-19. Medical science monitor: international medical journal of experimental and clinical research. 2020; 26: e926178. doi: 10.12659/MSM.926178.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Alroomi M, Rajan R, Omar AA, et al. Ferritin level: a predictor of severity and mortality in hospitalized COVID-19 patients. Immunity, inflammation and disease. 2021; 9(4): 1648-1655. doi: 10.1002/iid3.517.</mixed-citation><mixed-citation xml:lang="en">Alroomi M, Rajan R, Omar AA, et al. Ferritin level: a predictor of severity and mortality in hospitalized COVID-19 patients. Immunity, inflammation and disease. 2021; 9(4): 1648-1655. doi: 10.1002/iid3.517.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020; 18(4): 844-847. doi: 10.1111/jth.14768.</mixed-citation><mixed-citation xml:lang="en">Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020; 18(4): 844-847. doi: 10.1111/jth.14768.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020; 18(5): 1233-1234. doi: 10.1111/jth.14820.</mixed-citation><mixed-citation xml:lang="en">Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis. 2020; 18(5): 1233-1234. doi: 10.1111/jth.14820.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lillicrap D. Disseminated intravascular coagulation in patients with 2019nCoV pneumonia. Journal of thrombosis and haemostasis. 2020; 18(4): 786-787. doi: 10.1111/jth.14781.</mixed-citation><mixed-citation xml:lang="en">Lillicrap D. Disseminated intravascular coagulation in patients with 2019nCoV pneumonia. Journal of thrombosis and haemostasis. 2020; 18(4): 786-787. doi: 10.1111/jth.14781.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Zhao K, Wei H, et al. Dynamic relationship between D-dimer and COVID-19 severity. British journal of haematology. 2020; 190(1): e24-e27. doi: 10.1111/bjh.16811.</mixed-citation><mixed-citation xml:lang="en">Li Y, Zhao K, Wei H, et al. Dynamic relationship between D-dimer and COVID-19 severity. British journal of haematology. 2020; 190(1): e24-e27. doi: 10.1111/bjh.16811.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sui J, Noubouossie DF, Gandotra S, Cao L. Elevated plasma fibrinogen is associated with excessive inflammation and disease severity in COVID-19 patients. Frontiers in cellular and infection microbiology. 2021; 11: 734005. doi: 10.3389/fcimb.2021.734005.</mixed-citation><mixed-citation xml:lang="en">Sui J, Noubouossie DF, Gandotra S, Cao L. Elevated plasma fibrinogen is associated with excessive inflammation and disease severity in COVID-19 patients. Frontiers in cellular and infection microbiology. 2021; 11: 734005. doi: 10.3389/fcimb.2021.734005.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020; 63(3): 364-374. doi: 10.1007/s11427-020-1643-8.</mixed-citation><mixed-citation xml:lang="en">Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020; 63(3): 364-374. doi: 10.1007/s11427-020-1643-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Henry BM, Aggarwal G, Wong J, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. The American journal of emergency medicine. 2020; 38(9): 1722-1726. doi: 10.1016/j.ajem.2020.05.073.</mixed-citation><mixed-citation xml:lang="en">Henry BM, Aggarwal G, Wong J, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. The American journal of emergency medicine. 2020; 38(9): 1722-1726. doi: 10.1016/j.ajem.2020.05.073.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clinical Chemistry and Laboratory Medicine. 2020; 58(7): 1063-1069. doi: 10.1515/cclm-2020-0240.</mixed-citation><mixed-citation xml:lang="en">Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clinical Chemistry and Laboratory Medicine. 2020; 58(7): 1063-1069. doi: 10.1515/cclm-2020-0240.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">García de Guadiana-Romualdo L, Morell-García D, Rodríguez-Fraga O, et al. Cardiac troponin and COVID-19 severity: Results from BIOCOVID study. European journal of clinical investigation. 2021; 51(6): e13532. doi: 10.1111/eci.13532.</mixed-citation><mixed-citation xml:lang="en">García de Guadiana-Romualdo L, Morell-García D, Rodríguez-Fraga O, et al. Cardiac troponin and COVID-19 severity: Results from BIOCOVID study. European journal of clinical investigation. 2021; 51(6): e13532. doi: 10.1111/eci.13532.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
